Early switch from run-in with targeted to immunotherapy in advanced BRAF-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE. Livingstone, Dirk Schadendorf, Lidija Kandolf et al.|ESMO Open|2025Cited by 4